Quantitative Parameters of HLA-DQ Antibodies in Lung Transplantation

Launched by UNIVERSITY HOSPITAL, BORDEAUX · Mar 15, 2018

Keywords

ClinConnect Summary

This clinical trial is looking at a specific type of antibodies called anti-HLA DQ Donor Specific Antibodies (DSA) in patients who have undergone a lung transplant. The researchers want to understand how the levels and behavior of these antibodies relate to a condition known as Chronic Lung Allograft Dysfunction (CLAD), which can affect the long-term success of the transplant. By studying these antibodies, the goal is to identify new ways to predict which patients might develop CLAD, potentially leading to better management and treatment options.

To participate in this trial, individuals must be at least 18 years old and have received a lung transplant between January 2001 and July 2016. They should have developed specific anti-HLA DQ antibodies after their transplant and have enough blood samples stored for testing. Participants will not need to undergo any invasive procedures; instead, the study will analyze existing blood samples. If you join the trial, you may contribute to important discoveries that could improve care for future lung transplant patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18 years and older
• • Patient transplanted between 01/01/2001 and 31/07/2016
• • Patient with immunodominant anti-HLA DQ de novo DSA developed before 08/2016
• • Patient for who sufficient remaining serum quantity is available in usual care biobank
• • non-opposition of the patient
• Exclusion Criteria:
• • preformed DSA at the transplantation;
• • Non immunodominant DQ DSA ;
• • Insufficient serum quantity in usual care biobank
• • Inability to determine the date of DSA apparition at around one year
• • opposition of the patient